Targets › CDKN2A
1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout May 2027.
Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. (UniProt, P42771)
Open in Phaseline: the race on CDKN2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GCP-Service International West | RVU120 (SEL120) CDK 8/19 inhibitor | CDKN2A | Phase 2 | Low Risk Myelodysplastic Syndromes | May 2027 |
Low Risk Myelodysplastic Syndromes (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.